Janet Dillione Buys 6,147 Shares of CorMedix Inc. (NYSEAMERICAN:CRMD) Stock

CorMedix Inc. (NYSEAMERICAN:CRMD) Director Janet Dillione bought 6,147 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $8.19 per share, for a total transaction of $50,343.93. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

CorMedix stock traded up $0.19 during trading hours on Friday, hitting $8.11. 251,100 shares of the stock traded hands, compared to its average volume of 495,049. CorMedix Inc. has a 1 year low of $1.90 and a 1 year high of $13.70.

CorMedix (NYSEAMERICAN:CRMD) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.13 million.



Several brokerages recently weighed in on CRMD. TheStreet upgraded CorMedix from a “d+” rating to a “c-” rating in a research note on Friday, August 2nd. HC Wainwright set a $14.00 price target on CorMedix and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, Zacks Investment Research downgraded CorMedix from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 30th.

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of CorMedix by 12.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,032,482 shares of the biotechnology company’s stock valued at $9,262,000 after buying an additional 111,060 shares during the period. Private Advisor Group LLC lifted its holdings in shares of CorMedix by 40.4% in the 2nd quarter. Private Advisor Group LLC now owns 23,627 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 6,800 shares during the period. BlackRock Inc. lifted its holdings in shares of CorMedix by 231.5% in the 2nd quarter. BlackRock Inc. now owns 1,397,415 shares of the biotechnology company’s stock valued at $12,535,000 after buying an additional 975,813 shares during the period. Northern Trust Corp lifted its holdings in shares of CorMedix by 131.8% in the 2nd quarter. Northern Trust Corp now owns 103,431 shares of the biotechnology company’s stock valued at $928,000 after buying an additional 58,803 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of CorMedix by 178.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 78,231 shares of the biotechnology company’s stock valued at $701,000 after buying an additional 50,152 shares during the period.

CorMedix Company Profile

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Further Reading: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for CorMedix (NYSEAMERICAN:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.